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Abstract
Background In patients with resectable colorectal liver metastases (CRLM), distinct histopathological growth patterns 
(HGPs) develop at the interface between the tumour and surrounding tissue. The desmoplastic (d) HGP is characterised by 
angiogenesis and a peripheral fibrotic rim, whereas non-angiogenic HGPs co-opt endogenous sinusoidal hepatic vasculature. 
Evidence from previous studies has suggested that patients with dHGP in their CRLM have improved prognosis as compared 
to patients with non-desmoplastic HGPs. However, these studies were relatively small and applied arbitrary cut-off values 
for the determination of the predominant HGP. We have now investigated the prognostic effect of dHGP in a large cohort of 
patients with CRLM resected either with or without neoadjuvant chemotherapy.
Methods All consecutive patients undergoing a first partial hepatectomy for CRLM between 2000 and 2015 at a tertiary 
referral centre were considered for inclusion. HGPs were assessed in archival H&E stained slides according to recently 
published international consensus guidelines. The dHGP was defined as desmoplastic growth being present in 100% of the 
interface between the tumour and surrounding liver.
Results In total, HGPs in CRLMs from 732 patients were assessed. In the chemo-naive patient cohort (n = 367), the dHGP 
was present in 19% (n = 68) and the non-dHGP was present in 81% (n = 299) of patients. This dHGP subgroup was inde-
pendently associated with good overall survival (OS) (HR: 0.39, p < 0.001) and progression-free survival (PFS) (HR: 0.54, 
p = 0.001). All patients with any CRLM with a non-dHGP had significantly reduced OS compared to those patients with 
100% dHGP, regardless of the proportion of non-dHGP (all p values ≤ 0.001). In the neoadjuvantly treated patient cohort 
(n = 365), more patients were found to express dHGP (n = 109, 30%) (adjusted odds ratio: 2.71, p < 0.001). On univariable 
analysis, dHGP was associated with better OS (HR 0.66, p = 0.009) and PFS (HR 0.67, p = 0.002). However, after correc-
tion for confounding by means of multivariable analysis no significant association of dHGP with OS (HR 0.92, p = 0.623) 
or PFS (HR 0.76, p = 0.065) was seen.
Conclusions The current study demonstrates that the angiogenic dHGP in CRLM resected from chemo-naive patients acts 
as a strong, positive prognostic marker, unmatched by any other prognosticator. This observation warrants the evaluation of 
the clinical utility of HGPs in prospective clinical trials.
Keywords Histopathological growth pattern · Prognostic factor · Colorectal cancer · Liver metastases · Vessel co-option
Introduction
As hepatic tumours develop, histopathological growth pat-
terns (HGPs) appear at the interface between the tumour 
border and surrounding liver parenchyma. Previous studies 
have suggested that HGPs have the potential to predict both 
tumour biology and prognosis in patients with colorectal 
liver metastasis (CRLM). Three primary HGPs have been 
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identified in CRLM: desmoplastic (d), replacement (r) and 
the pushing (p) pattern [1]. Over time the classification of 
HGPs has evolved and ultimately resulted in international 
consensus guidelines. Applying these guidelines made the 
dHGP and rHGP the most common types and the pHGP 
fairly uncommon [2].
In addition to the fibrotic reaction (desmoplasia) that sur-
rounds the metastases, one of the predominant features of 
tumours which exhibit dHGP is angiogenesis. These tumours 
are characterised by elevated endothelial cell proliferation 
and regions of increased vessel density called vascular hot 
spots. The new blood vessels appear leaky and functionally 
impaired with fibrin deposits in the peri-vascular stroma 
[3]. This is in contrast to the rHGP, in which angiogenesis 
does not occur, the proportion of proliferating endothelial 
cells is very low and there are no obvious effects of VEGFA 
such as fibrin deposition [3]. In rHGP, vascularisation of the 
tumours is established by co-opting the existing sinusoidal 
blood vessels of the liver [3, 4]. As the name implies, cancer 
cells ‘replace’ the hepatocytes, while the stromal architec-
ture of the liver is maintained.
Tumours with rHGP exhibit features that have been 
associated with aggressive cancer biology and impaired 
prognosis, including increased cancer cell motility [4], 
non-angiogenic growth [4] and reduced infiltration of 
CD8+ immune cells [5, 6]. Previous studies evaluating the 
prognostic impact of HGPs suggest that the dHGP is associ-
ated with improved prognosis [2, 4, 5, 7–10]. These studies 
were relatively small and applied arbitrary cut-off values 
for the determination of the predominant growth pattern. 
If HGPs are an intrinsic reflection of tumour biology, one 
could hypothesise that the presence of any non-desmoplastic 
HGP (pHGP and/or rHGP) could be of prognostic value. 
The current study investigated the association of dHGP with 
survival in a large cohort of patients undergoing resection of 
CRLM, and the potential correlation between neoadjuvant 
chemotherapy and HGPs.
Methods
Patient selection and data
All consecutive patients who underwent laparotomy for sur-
gical treatment of CRLM between January 2000 and March 
2015 at the Erasmus MC Cancer Institute were considered 
for inclusion. The Erasmus MC Cancer Institute is a tertiary 
referral centre for liver surgery. Patients without complete 
surgical treatment (i.e. resection with or without ablation 
of all known CRLM) with curative intent were excluded. 
In addition, patients treated with ablation only were also 
excluded. Clinicopathological data on primary tumour, 
CRLM and recurrent metastatic disease were obtained 
from a prospectively maintained database. HGP assessment 
was performed retrospectively on H&E stained tissues sec-
tions from archival tissue. The current study was performed 
according to the REMARK guidelines and approved by the 
medical ethics committee of the Erasmus University Medi-
cal Centre Rotterdam (MEC-2016-046) [11].
Prognosis
The primary objective of this study was to evaluate the asso-
ciation between HGPs and prognosis after first hepatectomy 
for CRLM. In order to analyse this, HGP data of the first 
hepatectomy were evaluated (i.e. for the survival analyses 
recurrent CRLM treated with repeat hepatectomy were not 
evaluated). Survival was measured as progression-free sur-
vival (PFS) and overall survival (OS). The PFS was defined 
as the time in months between resection of CRLM and diag-
nosis of progression of disease or death, whichever occurred 
first. Disease progression was diagnosed by radiological or 
histological assessment. The OS was defined as the time in 
months between surgery for CRLM and death.
Effect of chemotherapy
The secondary objective was to assess the potential associa-
tion between chemotherapy and the prevalence of HGPs. In 
order to do so, distribution of HGPs amongst chemo-naive 
and neoadjuvantly treated patients was compared. Patients 
who had received any chemotherapy within the 6 months 
prior to the liver resection were considered neoadjuvantly 
treated. Patients with a liver recurrence undergoing repeat 
resection at the Erasmus MC Cancer Institute were identi-
fied and subsequently stratified into four distinct treatment 
groups: chemo-naive at both hepatectomies (−/−), neoad-
juvantly treated at the first hepatectomy but chemo-naive at 
the second (+/−), chemo-naive at the first hepatectomy but 
neoadjuvantly treated at the second (−/+) and lastly neoad-
juvantly treated at both hepatectomies (+/+). Specifically 
for this secondary objective, the HGPs of these recurrent 
CRLM were determined as well and the prevalence of HGPs 
at first and second hepatectomy was compared across these 
four distinct treatment groups.
Chemotherapy and follow‑up
In accordance with the Dutch national guidelines, (neo)
adjuvant chemotherapy is not standard of care for patients 
with CRLM. Only in case of initially marginally resectable, 
synchronous and/or multiple (≥ 4) resectable CRLM is neo-
adjuvant chemotherapy considered. A proportion of patients 
received neoadjuvant chemotherapy in the referring hospital 
prior to admission. None of the patients received adjuvant 
chemotherapy.
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Post-operative surveillance is performed for up to 5 years 
after surgery for CRLM, using thoracoabdominal computed 
tomography (CT) and carcinoembryonic antigen (CEA)-
level measurements every 3–6 months for 3 years and then 
annually thereafter. After 5 years, further surveillance was 
performed by the general practitioner. Patients were cen-
sored for PFS at date of last follow-up if without disease 
progression.
Pathological assessment and description of HGPs
HGPs were determined according to the international con-
sensus guidelines of the Liver Metastasis Research Net-
work [2] blinded for patient outcome. HGPs were assessed 
per patient in all available haematoxylin and eosin (H&E) 
stained sections from all resected CRLM. In each slide, the 
interface between tumour border and normal liver paren-
chyma was evaluated using light microscopy by at least 
three trained observers (PV, ES, RC, BG, PN, DH). As 
some CRLM display a combination of HGPs, the entire 
tumour–liver interface was evaluated for each tissue sec-
tion. When multiple HGPs were present at the interface, 
the HGP was scored as a relative proportion of the inter-
face in which each of dHGP, rHGP and/or pHGP occurred. 
Every fraction of the tumour–liver interface, accounting for 
5% or more of the total interface of a metastasis, was taken 
into account. Average HGP scores were then calculated for 
each metastasis (in case of multiple slides per CRLM) and 
patient (in case of multiple CRLM). Tissue sections were 
considered not suitable for HGP assessment when less 
than 20% interface was available, when the quality of the 
H&E tissue section was insufficient for reliable assessment 
or when viable tumour tissue was absent [2]. Examples of 
H&E tissue sections with CRLM displaying dHGP, rHGP 
and pHGP are shown in Fig. 1a–f. In the dHGP, the cancer 
cells of the metastasis are separated from the liver tissue 
by a rim of desmoplastic tissue. The metastasis does not 
mimic the liver architecture and there is no direct contact 
between cancer cells and hepatocytes (Fig. 1a, b). There is 
often a dense lymphocytic infiltrate at the interface of the 
desmoplastic rim and the liver tissue. A ‘ductular reaction’, 
or proliferation of bile ducts, can sometimes be seen sur-
rounding the desmoplastic metastasis. In the pHGP, the liver 
cell plates that surround the metastasis are pushed away and 
compressed (Fig. 1e, f). There is no desmoplastic rim sur-
rounding the metastasis but also no direct contact between 
cancer cells and hepatocytes within the liver cell plates. As 
in the dHGP, the metastasis does not mimic the liver archi-
tecture. In the rHGP, cancer cells form cell plates that are in 
continuity with the liver cell plates (Fig. 1c, d). This permits 
the cancer cells to replace the hepatocytes within the liver 
cell plates and allows these metastases to co-opt the sinu-
soidal blood vessels at the tumour–liver interface, without 
inducing sprouting angiogenesis. The liver cell plates can 
sometimes be pushed away while the cancer cells replace 
the hepatocytes.
HGP categorisation
In order to investigate the hypothesis that the presence of any 
non-dHGP determines prognosis, patients were categorised 
as non-dHGP if any other HGP than dHGP was observed. 
For supplementary analyses, patients were also categorised 
according to the 50% cut-off value of the consensus guide-
lines in which case patients were categorised as dHGP, 
rHGP and pHGP when > 50% of the interface was scored as 
such. If none of the three HGP was present at > 50% of the 
interface, this was defined as mixed HGP and patients were 
excluded for further analysis, since no predominant HGP 
could be determined. In order to compare the angiogenic 
dHGP to the non-angiogenic rHGP, supplementary analy-
ses were also performed for patients with any proportion 
of rHGP compared to patients with pure (100%) dHGP. To 
that end, patients without any rHGP in the non-dHGP group 
were excluded. In this way, the rare pHGP was excluded 
from the analyses.
Statistical analysis method
Absolute numbers and percentages were used to present cat-
egorical data, while medians (incl. interquartile range (IQR)) 
were used to display continuous data. The Chi-squared test 
was used to evaluate differences in proportions. To compare 
medians between two or three groups the Mann–Whitney U 
or the Kruskal–Wallis test were used, respectively. Survival 
was estimated by means of Kaplan–Meier analysis, and the 
curves were computed until 60 months and compared using 
the logrank test. Uni- and multivariable Cox regression anal-
ysis was performed to determine if HGPs remained signifi-
cantly prognostic when correcting for well-known risk factors. 
Results of the Cox regression analyses were expressed using 
hazard ratios (HR) and consequent 95% confidence intervals 
(CI). In order to test possible statistical interaction between 
neoadjuvant chemotherapy and the HGP, an interaction term 
was added to a multivariable Cox regression model analys-
ing the entire study population. Other potential confounders 
corrected for were age, ASA score, primary tumour location, 
pathological T-stage, nodal status, disease-free interval, num-
ber of CRLM, diameter of the largest CRLM, carcinoembry-
onic antigen level, resection margin and extrahepatic disease. 
Uni- and multivariable binary logistic regression analysis was 
performed to determine whether the administration of neoad-
juvant chemotherapy was associated with the HGP that was 
observed. Results of the logistic regression were expressed 
using odds ratios (OR) and corresponding 95% CI. All analy-
ses were performed for chemo-naive and neoadjuvantly treated 
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patients separately where applicable. Median follow-up time 
for survivors was estimated using the reversed Kaplan–Meier 
method. No imputation of missing data was applied. Schoe-
nfeld residuals (for continuous variables) and Kaplan–Meier 
graphs (for categorical variables) were evaluated, in order to 
determine whether the proportional hazards assumption was 
violated. All statistical tests were two-sided and a p value 
below 0.05 was considered statistically significant. All analy-
ses were performed using SPSS version 24.0 (SPSS Inc., Chi-
cago, IL) and R version 3.5.1 (http://www.r-proje ct.org).
Results
Patient characteristics
During the study period, 964 consecutive patients under-
went laparotomy for intended first surgical treatment 
of CRLM. One hundred patients (10%) were excluded 
because no complete surgical treatment was performed. In 
132 patients (15%), HGP assessment was not possible due 
Fig. 1  a–f Collated HE tissue sections. a, b dHGP low and high magnification; c, d rHGP low and high magnification; e, f pHGP low and high 
magnification. T: tumour; D: desmoplastic stroma; L: liver parenchyma
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to missing H&E tissue sections (n = 55), ablative therapy 
only (n = 21) or H&E tissue sections which were non-
suitable for HGP determination (n = 56). Ultimately, the 
HGP could be determined in 732 patients. In 177 patients 
(24%), dHGP was observed and the other 555 patients 
(76%) all displayed to some extent a proportion of non-
dHGP. A flowchart of the patient inclusion is presented 
in supplementary Fig. 1. Median follow-up time for the 
survivors was 76 months (IQR: 45–116 months), during 
which time 528 patients (70%) were diagnosed with dis-
ease progression and 428 patients (58%) died. Statistical 
interaction between neoadjuvant chemotherapy and HGP 
proved significant (p = 0.005) on multivariable analysis.
HGP in chemo‑naive patients
Of the 732 patients assessed, 367 (50%) did not receive 
neoadjuvant chemotherapy. In this subgroup of patients, 68 
Fig. 2  a Distribution of HGPs. 
Ranking based on percentage 
dHGP. a Distribution of HGPs 
in the chemo-naive cohort. b 
Distribution of HGPs in the 
pre-treated cohort. c, d Total 
proportion rHGP (c) and dHGP 
(d) in chemo-naive patients 
compared to pre-treated patients 
(percentages do not always add 
up to 100% due to rounding)
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(19%) displayed dHGP only while n = 214 (58%) displayed 
dHGP in combination with non-dHGP, and n = 85 (23%) dis-
played no dHGP. In total, 299 patients (81%) displayed some 
proportion of non-dHGP (Fig. 2a). Baseline characteristics 
compared for the presence of any non-dHGP are displayed 
in supplementary table 1.
Patients with dHGP had a 5-year OS rate of 78% com-
pared to 37% of patients with any non-dHGP (Fig. 3a). After 
correction for potential confounders, dHGP remained sig-
nificantly associated with improved OS (adjusted HR 0.39, 
p < 0.001) compared to non-dHGP (Table 1). Similar results 
were obtained for PFS. The 5-year PFS rate of patients with 
dHGP was 50% compared to 19% of patients with any non-
dHGP. On multivariable analysis dHGP also remained sig-
nificantly associated with improved PFS (adjusted HR 0.54, 
p = 0.001) (Table 1; Fig. 4a).
When the OS for different percentages of non-dHGP was 
evaluated (Fig. 3b), there were no differences in OS between 
patients who displayed any non-dHGP, regardless of the per-
centage of non-dHGP (all p values > 0.2). Kaplan–Meier 
analysis showed that all patients with any non-dHGP had 
significantly impaired survival compared to patients who 
had (100%) dHGP (all p values ≤ 0.001). This finding was 
confirmed on multivariable analysis (Table 2).
HGP in neoadjuvantly treated patients
In total, 365 patients (50%) received chemotherapy within 
6 months prior to liver resection. The distribution of HGPs 
amongst neoadjuvantly treated patients is displayed in 
Fig. 2b. Baseline characteristics of neoadjuvantly treated 
patients compared for the presence of any non-dHGP are 
displayed in supplementary table 2. Patients who were 
treated neoadjuvantly with chemotherapy had a more severe 
disease burden (Supplementary table 3). The chemothera-
peutic regimen was oxaliplatin-based in 309 patients (85%) 
and irinotecan based in 34 (9%). Fifteen patients received 
a 5-Fluorouracil derivative only (4%). Six patients (2%) 
received a combination of oxaliplatin and irinotecan and in 
one patient the type of chemotherapy was unknown. In 119 
patients (33%), bevacizumab was added to the chemotherapy 
regimen.
Of the neoadjuvantly treated patients, 109 (30%) had 
dHGP and 256 (70%) displayed a proportion of non-dHGP 
(Fig. 2b). dHGP was observed in a greater number of sam-
ples from neoadjuvantly treated than chemo-naive patients 
(30% vs. 19%, p < 0.001). The total proportion of any 
dHGP in neoadjuvantly treated patients was 66%, while 
this was 41% in chemo-naive patients. A similar difference 
was observed for the total proportion of any rHGP (both 
p < 0.001, Fig. 2c, d). The association between neoadjuvant 
chemotherapy and the presence of dHGP remained sig-
nificant (adjusted OR 2.71, p < 0.001) after correction for Fig
. 3
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several clinicopathological characteristics (Supplementary 
table 4).
The addition of bevacizumab to the chemotherapeutic 
regimen was not associated with a significant increase of 
the proportion of dHGP (35% vs. 27%, p = 0.120). A subse-
quently performed multivariable logistic regression model 
failed to demonstrate a significant association between 
dHGP and the administration of bevacizumab (adjusted OR 
1.60, p = 0.077) (Supplementary table 5).
Five-year OS in neoadjuvantly treated patients with 
dHGP was 53%, while a 5-year OS of 40% was seen in 
patients with non-dHGP (Fig. 3c, p = 0.012). When cor-
recting for confounders, no significant association of 
dHGP was observed for OS (adjusted HR 0.98, p = 0.623) 
(Table 3). Again, similar results were obtained for the PFS. 
Neoadjuvantly treated patients with dHGP had a 5-year 
PFS rate of 26% compared to 14% in patients with non-
dHGP (Fig. 4b, p = 0.004). On multivariable analysis, only 
a trend towards a significant association of dHGP with PFS 
was seen (adjusted HR 0.76, p = 0.065) (Table 3).
Additional Kaplan–Meier analyses showed no over-
all survival difference when adding bevacizumab to the 
chemotherapeutic regimen in the total group (p = 0.754), 
in the non-dHGP (p = 0.854) or in the dHGP subgroup 
(p = 0.411). Similar results were found for PFS in the total 
group (p = 0.806), the non-dHGP (p = 0.829) or the dHGP 
subgroup (p = 0.806). Subsequent multivariable analysis 
in the total neoadjuvantly treated group with bevacizumab 
entered as potential confounder showed no significant 
association of bevacizumab with OS (adjusted HR 1.06, 
p = 0.702; supplementary table 6.) or PFS (adjusted HR 
1.09, p = 0.540; supplementary table 7).
Table 1  Cox regression analysis for OS and PFS of chemo-naive patients
ASA American Society of Anaesthesiologists, CEA carcinoembryonic antigen, cont. continuous, CRLM colorectal liver metastases, dHGP des-
moplastic histopathological growth pattern, R1 irradical resection margin
Overall survival Univariable Multivariable
Variable Hazard ratio [95% CI] p Value Hazard ratio [95% CI] p Value
Age at resection CRLM (cont.) 1.011 [0.997–1.025] 0.126 1.016 [1.002–1.032] 0.030
ASA > II 1.018 [0.648–1.600] 0.939 0.985 [0.614–1.579] 0.949
Right-sided primary 1.477 [1.053–2.072] 0.024 1.539 [1.074–2.207] 0.019
pT3-4 1.191 [0.852–1.666] 0.306 0.902 [0.626–1.300] 0.579
Node-positive primary 1.459 [1.102–1.933] 0.008 1.570 [1.140–2.164] 0.006
Disease-free interval (cont.) 0.997 [0.991–1.004] 0.454 0.990 [0.983–0.998] 0.011
Number of CRLM (cont.) 1.145 [1.031–1.273] 0.012 1.095 [0.969–1.237] 0.144
Diameter largest CRLM (cont.) 1.099 [1.041–1.162] < 0.001 1.102 [1.026–1.185] 0.008
Preoperative CEA level (cont.) 1.001 [1.000–1.002] 0.003 1.001 [1.000–1.002] 0.063
R1 resection CRLM 1.321 [0.892–1.956] 0.165 1.116 [0.738–1.685] 0.603
Extra hepatic disease 1.495 [0.896–2.496] 0.124 1.688 [0.930–3.066] 0.085
dHGP 0.314 [0.191–0.515] < 0.001 0.394 [0.233–0.667] < 0.001
Progression-free survival Univariable Multivariable
Variable Hazard ratio [95% CI] p Value Hazard ratio [95% CI] p Value
Age at resection CRLM (cont.) 0.998 [0.987–1.010] 0.769 1.005 [0.993–1.018] 0.387
ASA > II 0.836 [0.554–1.262] 0.394 0.852 [0.555–1.306] 0.462
Right-sided primary 1.179 [0.868–1.602] 0.291 1.232 [0.893–1.698] 0.204
pT3-4 1.175 [0.878–1.573] 0.279 0.873 [0.634–1.203] 0.407
Node-positive primary 1.566 [1.224–2.002] < 0.001 1.558 [1.184–2.049] 0.002
Disease-free interval (cont.) 0.993 [0.986-1.000] 0.039 0.989 [0.981–0.996] 0.003
Number of CRLM (cont.) 1.215 [1.102–1.340] < 0.001 1.150 [1.029–1.285] 0.013
Diameter largest CRLM (cont.) 1.026 [0.972–1.083] 0.345 1.036 [0.970–1.107] 0.287
Preoperative CEA level (cont.) 1.001 [1.000-1.002] 0.041 1.001 [1.000-1.002] 0.167
R1 resection CRLM 1.620 [1.149–2.285] 0.006 1.376 [0.956–1.982] 0.086
Extra hepatic disease 1.199 [0.760–1.892] 0.434 1.596 [0.953–2.672] 0.076
dHGP 0.452 [0.317–0.645] < 0.001 0.536 [0.366–0.786] 0.001
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Consensus cut‑off
Supplementary analyses performed using the consensus 
guidelines > 50% predominant HGP cut-off confirmed 
results: superior survival for dHGP, higher proportion of 
dHGP after neoadjuvant chemotherapy and loss of prog-
nostic impact of dHGP in neoadjuvantly treated patients. 
These data are presented in supplementary tables 8–12 
and supplementary Fig. 2a, b.
dHGP versus any rHGP
In order to make a direct comparison of angiogenic dHGP 
versus non-angiogenic rHGP growth, we have performed 
separate, supplementary analyses which excluded the few 
cases with angiogenic pHGP. Patients with any proportion 
of rHGP were compared to patients with pure (100%) dHGP, 
excluding patients without any rHGP from the non-dHGP 
group. In total, 26 patients, of which 13 were chemo-naive, 
without rHGP were observed in the non-dHGP group and 
excluded for these analyses. Again, all analyses had simi-
lar results: superior OS (HR 0.40, p < 0.001) and PFS (HR 
0.55, p = 0.002) for chemo-naive patients with dHGP and 
a reduced prognostic impact of HGPs after neoadjuvant 
chemotherapy (OS—HR: 0.88, p = 0.505; PFS—HR: 0.73, 
p = 0.032).
HGP comparison of multiple hepatectomies
Amongst the included patients, the HGP of recurrent CRLM 
could be determined in 66 patients. A similar proportional 
distribution of HGPs was observed in these patients. 
After surgery for recurrent CRLM without neoadjuvant 
chemotherapy, dHGP tumours were found in 18% (8/45) 
of patients, compared to 29% (6/21) in patients who did 
receive chemotherapy (p = 0.318). Four groups (−/−, +/−, 
−/+, +/+), as described in the methods, were created. Fig-
ure 5a–d graphically displays the changes in HGPs found 
per group. The difference in proportion HGPs between the 
first and second surgery was significant in the +/− group 
(Fig. 5b, p = 0.007). The other changes in proportions of 
HGP between the first and second surgery were not signifi-
cant (all p values > 0.250).
Discussion
The current study demonstrates that HGPs have signifi-
cant prognostic potential for colorectal cancer patients 
who undergo first resection of CRLM. Our results indicate 
that in chemo-naive patients the presence of a pure dHGP 
predicts improved survival with a hazard ratio unmatched 
by any clinicopathological or biological correlate to date 
[12, 13]. This is the first study to show that the presence of 
any non-dHGP is sufficient to indicate impaired prognosis. 
Interestingly, chemotherapy is associated with an increased 
incidence of CRLM displaying dHGP in the current patient 
cohort and the prognostic impact of dHGP is reduced in 
these patients.
Stratifying patient groups for preoperative treatment 
status showed that the proportion and prognostic impact 
of HGPs differs significantly between chemo-naive and 
neoadjuvantly treated patients. Previous studies examined 
Fig. 4  a PFS of chemo-naive patients. b PFS of pre-treated patients
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relatively small and heterogeneous patient groups which 
hampered adequate multivariable analysis, whereas the large 
number of events in the current study ensured that proper 
correction for confounders could be performed [4, 7–10]. In 
addition, preceding studies did not perform cut-off analyses 
for different proportions of HGPs. The currently performed 
cut-off analysis showed that an increasing proportion of 
non-dHGP was not associated with a decrease in prognosis. 
Therefore, the presence of any non-dHGP, rather than the 
actual proportion of the tumour–liver interface occupied 
by non-dHGP, dictates worse survival compared to patients 
with 100% dHGP. This suggests that an arbitrary cut-off 
should not be applied to define the non-dHGP growth pat-
tern. This information can be integrated in future consensus 
guidelines for scoring the HGPs of CRLM.
Neoadjuvant chemotherapy (with or without bevaci-
zumab) has been associated with tumoural fibrosis and 
necrosis in CRLM [14, 15]. Treatment with bevacizumab 
has been associated with alterations in the extracellular 
matrix (ECM) of CRLM [16] and the ECM has been 
argued to influence the hallmarks of cancer [17]. Given 
these associations, one could hypothesise that treating 
CRLM with chemotherapy with or without bevacizumab 
could induce alterations in the HGP. In the current study, 
it has been possible to determine the prevalence of dif-
ferent HGP types in CRLM relative to chemotherapy sta-
tus and with the addition of bevacizumab. We observed a 
higher proportion of 100%dHGP in neoadjuvantly treated 
patients, but the prognostic impact of this growth pattern 
was relatively reduced in this patient category. Similar 
results were found within the subgroup in whom bevaci-
zumab was added to the chemotherapy regimen, but this 
was not significantly different compared to the group that 
was treated neoadjuvantly without bevacizumab. Moreo-
ver, the previously reported survival benefit of the addition 
of bevacizumab to chemotherapy in 51 patients with dHGP 
[4] could not be demonstrated in the current study. At our 
institution, evident progressive disease during chemo-
therapy is a contra-indication for surgical treatment of 
CRLM. As poor pathological and radiological response is 
associated with rHGP [4], it is possible that progressive 
patients have CRLM displaying non-dHGP. This could 
have resulted in a higher relative proportion of dHGP in 
the neoadjuvantly treated patient cohort. Unfortunately, 
data on the percentage of patients that were not operated 
upon because of disease progression are unavailable in 
our series. In randomised setting, approximately 7% of 
patients with resectable CRLM display progressive dis-
ease during chemotherapy [18]. In addition, considerable 
differences in clinical risk were seen when comparing 
chemo-naive patients with neoadjuvantly treated patients 
in this non-randomised cohort. An alternative explanation 
for both the larger proportion of dHGP and the reduced 
prognostic impact of HGPs in the neoadjuvantly treated 
cohort is that a biological response to chemotherapy is a 
histological conversion to dHGP, the relevance of which 
we have yet to determine. Of patients considered chemo-
naive for their recurrent CRLM, 18% (8/45) had recur-
rent CRLM displaying dHGP compared to 29% (6/21) in 
patients treated neoadjuvantly for their recurrent CRLM. 
This difference in proportional distribution of recurrent 
HGPs was not significant. Nevertheless, it was similar to 
the proportional distribution of HGPs observed after first 
hepatectomy in which the difference was significant. When 
Table 2  Overall survival cox 
regression cut-off analysis in the 
chemo-naive cohort
Overall survival Univariable Multivariable
Variables Hazard ratio [95% CI] p Value Hazard ratio [95% CI] p Value
Age at resection CRLM (cont.) 1.011 [0.997–1.025] 0.126 1.017 [1.002–1.032] 0.031
ASA > II 1.018 [0.648–1.600] 0.939 0.968 [0.600–1.564] 0.896
Right-sided primary 1.477 [1.053–2.072] 0.024 1.563 [1.088–2.247] 0.016
pT3-4 1.191 [0.852–1.666] 0.306 0.890 [0.617–1.285] 0.535
Node-positive primary 1.459 [1.102–1.933] 0.008 1.583 [1.142–2.194] 0.006
Disease-free interval (cont.) 0.997 [0.991–1.004] 0.454 0.990 [0.982–0.998] 0.010
Number of CRLM (cont.) 1.145 [1.031–1.273] 0.012 1.104 [0.974–1.252] 0.122
Diameter largest CRLM (cont.) 1.099 [1.041–1.162] < 0.001 1.105 [1.026–1.189] 0.008
Preoperative CEA level (cont.) 1.001 [1.000–1.002] 0.003 1.001 [1.000–1.002] 0.103
R1 resection CRLM 1.321 [0.892–1.956] 0.165 1.103 [0.727–1.671] 0.645
Extra hepatic disease 1.495 [0.896–2.496] 0.124 1.627 [0.886–2.987] 0.116
100% dHGP Ref Ref
 0.1–33% non-dHGP 2.851 [1.582–5.137] < 0.001 2.350 [1.248–4.425] 0.008
 33.1–67% non-dHGP 2.840 [1.547–5.215] < 0.001 2.458 [1.303–4.639] 0.005
 67.1–99.9% non-dHGP 3.255 [1.924–5.505] < 0.001 2.443 [1.393–4.284] 0.002
 100% non-dHGP 3.535 [2.055–6.084] < 0.001 2.858 [1.605–5.088] < 0.001
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taking neoadjuvant treatment status of both resections into 
account, in the +/− group 35% (8/23) changed from dHGP 
(first surgery) to non-dHGP (second surgery), while this 
change was only seen in 5% (1/22) of the −/− group. These 
data could support the hypothesis of potential conversion 
of the HGP as a consequence of chemotherapy. An alterna-
tive explanation for this observation could be that patients 
who at first have dHGP CRLM, but develop non-dHGP 
CRLM at recurrence as the disease might acquire a more 
aggressive tumour biology. In addition, Frentzas et al. also 
found a relatively large proportion of rHGP in recurrent 
CRLM, albeit after combination therapy of chemotherapy 
and bevacizumab for the recurrent CRLM [4]. The value 
of these data remains limited, because of its retrospec-
tive nature, selected population and low patient numbers. 
Further study of the HGPs in chemo-naive versus neoadju-
vantly treated CRLM is required to investigate this concept 
and, more specifically, data from randomised studies will 
be needed to further evaluate this hypothesis.
The biological mechanisms that underlie the associa-
tion of non-dHGP with impaired survival remain largely 
unknown. The non-dHGP cohort in this study consists 
almost exclusively of patients with liver metastases that 
display the vessel co-opting, non-angiogenic rHGP. An 
important difference between rHGP and dHGP is indeed 
the mechanism of vascularisation. The desmoplastic growth 
pattern of liver metastases has an elevated fraction of pro-
liferating endothelial cells and blood vessels are organised 
in vascular hot spots [3, 19], both clear features of angio-
genesis. The vascular architecture of the metastasis does not 
resemble the vascular architecture of the adjacent liver tis-
sue. These findings also apply to the pushing growth pattern. 
In the replacement growth pattern, on the contrary, a low 
endothelial cell proliferation fraction and a lack of vascular 
Table 3  Cox regression analysis for OS and PFS of pre-treated patients
ASA American Society of Anaesthesiologists, CEA carcinoembryonic antigen, cont. continuous, CRLM colorectal liver metastases, dHGP des-
moplastic histopathological growth pattern, R1 irradical resection margin
Overall survival Univariable Multivariable
Variable Hazard ratio [95% CI] p Value Hazard ratio [95% CI] p Value
Age at resection CRLM (cont.) 1.021 [1.007–1.036] 0.003 1.034 [1.016–1.051] < 0.001
ASA > II 1.082 [0.675–1.733] 0.744 1.197 [0.728–1.968] 0.479
Right-sided primary 0.877 [0.590–1.304] 0.517 0.954 [0.624–1.459] 0.829
pT3-4 1.476 [0.988–2.204] 0.057 1.402 [0.900–2.183] 0.135
Node-positive primary 1.419 [1.050–1.918] 0.023 1.383 [0.994–1.923] 0.054
Disease-free interval (cont.) 0.996 [0.985–1.008] 0.541 0.995 [0.982–1.008] 0.452
Number of CRLM (cont.) 1.023 [0.976–1.072] 0.340 1.051 [0.995–1.111] 0.076
Diameter largest CRLM (cont.) 0.997 [0.952–1.045] 0.905 1.026 [0.969–1.086] 0.381
Preoperative CEA level (cont.) 1.000 [1.000–1.000] 0.955 1.000 [1.000–1.000] 0.574
R1 resection CRLM 1.374 [0.989–1.908] 0.058 1.273 [0.867–1.869] 0.218
Extra hepatic disease 1.705 [1.222–2.380] 0.002 1.761 [1.196–2.592] 0.004
dHGP 0.661 [0.484–0.902] 0.009 0.915 [0.643–1.302] 0.623
Progression-free survival Univariable Multivariable
Variable Hazard ratio [95% CI] p Value Hazard ratio [95% CI] p Value
Age at resection CRLM (cont.) 1.008 [0.996–1.019] 0.188 1.011 [0.998–1.025] 0.106
ASA > II 1.086 [0.731–1.614] 0.682 1.045 [0.682–1.600] 0.840
Right-sided primary 0.936 [0.684–1.282] 0.681 1.053 [0.752–1.474] 0.764
pT3-4 1.420 [1.021–1.974] 0.037 1.440 [1.005–2.065] 0.047
Node-positive primary 1.328 [1.032–1.710] 0.028 1.143 [0.869–1.501] 0.339
Disease-free interval (cont.) 0.994 [0.985–1.004] 0.234 0.996 [0.986–1.007] 0.462
Number of CRLM (cont.) 1.026 [0.989–1.063] 0.174 1.036 [0.992–1.081] 0.109
Diameter largest CRLM (cont.) 0.993 [0.954–1.034] 0.728 1.000 [0.955–1.048] 0.986
Preoperative CEA level (cont.) 1.000 [1.000–1.000] 0.462 1.000 [1.000–1.000] 0.443
R1 resection CRLM 1.464 [1.101–1.948] 0.009 1.449 [1.043–2.015] 0.027
Extra hepatic disease 1.777 [1.321–2.390] < 0.001 1.912 [1.367–2.674] < 0.001
dHGP 0.671 [0.519–0.867] 0.002 0.762 [0.570–1.017] 0.065
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hot spots are observed [3, 19]. The tumour tissue mimics the 
liver tissue by growing along and using the sinusoidal blood 
vessels. The preservation of the normal tissue architecture is 
indicative of non-angiogenic tumour growth. The co-opted 
capillary bed from normal liver is highly efficient and liver 
metastases with a rHGP display minimal hypoxia and vascu-
lar leakage as opposed to the desmoplastic liver metastases 
with their vasculature created in an angiogenic environment 
in which tortuous, disrupted, leaking and dysfunctional 
blood vessels result in hypoxia [3]. The association between 
growth patterns and the means of tumour vascularisation 
(by angiogenesis or by vessel co-option) is not limited to 
tumour growth in the liver, but has also been described in, 
for example, the lungs, the lymph nodes and the skin [20]. 
The motile and invasive cancer cells present in replacement 
metastases enables the incorporation of normal surrounding 
tissue stroma and creates the typical irregular tumour border. 
Up-regulation of signalling pathways of cell motility has 
been described in pre-clinical models of CRC liver metas-
tases and primary liver cancer [4, 21]. Similarly, molecular 
signatures of cancer cell motility and invasion have been 
identified in angiotropism, a process of peri-vascular growth 
that closely resembles vascular co-option during replace-
ment growth [22, 23]. Co-localisation of cancer cells and 
endothelial cells during vascular co-option also results in 
angiocrine signalling. Soluble ligands of the notch-pathway 
produced by endothelial cells induce stemness in adjacent 
cancer cells which is associated with both cancer cell motil-
ity and with resistance to chemotherapy [24]. Again, simi-
lar observations have been reported for angiotropic tumours 
Fig. 5  a–d Graphical display of the changes in HGPs between first and second surgery for CRLM found per group: a −/−; b +/−; c −/+; d +/+
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[23]. Beyond the intrinsic changes in the tumour and stroma 
observed in replacement metastases, an effective immune 
response in patients with dHGP also might contribute to the 
difference in survival outcomes between these two HGPs 
[5, 25]. Brunner et al. demonstrated that capsule formation 
in dHGP strongly correlates with high levels of peri-tumour 
infiltration of CD4+, CD45RO+ and CD8+ cells [5]. Taken 
together, these findings corroborate the less favourable prog-
nosis of patients with liver metastases that have the ability 
to perform non-desmoplastic growth.
For a more direct comparison of angiogenic dHGP and 
non-angiogenic rHGP growth, we have excluded the few 
cases with angiogenic pHGP in separate analyses. Non-
angiogenic replacement HGP has been associated with 
aggressive tumour growth in which normal sinusoidal liver 
capillaries are co-opted by the metastasis. The pHGP can be 
difficult to distinguish from the rHGP when during replace-
ment growth the liver cell plates are also pushed aside. This 
HGP assessment problem has been extensively addressed in 
the international consensus for scoring the histopathological 
growth patterns of liver metastases [2]. This, however, is an 
additional reason to selectively study the impact on survival 
of pure (100%) dHGP. It will be necessary to assemble a 
large cohort of patients with pHGP to accurately study the 
impact of this growth pattern on outcome.
The results of the current study should be interpreted in 
the light of its limitations. The HGP data were collected 
retrospectively, in 55 potentially eligible patients tissue sec-
tions were missing and there were 56 patients with unsuit-
able H&E tissue sections. It was also not possible to exam-
ine CRLM from patients with progressive disease during 
chemotherapy as this as a contra-indication for surgical 
treatment at our institution. This study was also limited by 
the unavailability of RAS and BRAF mutational status. Both 
mutations have been suggested as prognostic biomarkers for 
survival after liver resection for CRLM [13, 26, 27] In addi-
tion, Brudvik et al. proposed an enhanced clinical risk score, 
including the RAS mutational status. The authors demon-
strated improved performance of the prognostic model 
[28]. In an attempt to overcome this shortcoming, the cur-
rent study was corrected for right-sidedness of the primary 
tumour, which is associated with KRAS [29, 30] and BRAF 
[29–31] mutational status.
In conclusion, the current study demonstrates in the 
largest patient cohort to date with multivariable analyses 
that HGPs, distinguishing angiogenic from non-angiogenic 
growth, have considerable prognostic impact in patients 
who are treated surgically for CRLM. The presence of any 
non-desmoplastic, non-angiogenic HGP displaying vessel 
co-opting growth, rather than the actual proportion of non-
dHGP, determines prognosis suggesting that future studies 
and guidelines should focus upon this distinction.
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